Valeant subpoenaed by U.S. prosecutors; shares drop
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Valeant's (VRX) Buy Rating Reiterated at BofA/Merrill Lynch
October 15, 2015 10:12 AM EDTBofA/Merrill Lynch reiterated a Buy rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $290. Analyst Sumant S. Kulkarni said while volatility is expected, due to overly conservative DCF scenarios on pricing, weakness could present a "particularly good opportunity."
BofA/Merrill... More
